These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24532044)

  • 1. Subcutaneous bortezomib incorporated into the bortezomib-thalidomide-dexamethasone regimen as part of front-line therapy in the context of autologous stem cell transplantation for multiple myeloma.
    Lok A; Mocquard J; Bourcier J; Redelsperger L; Bonnet A; Chauvin C; Thomaré P; Mahé B; Touzeau C; Moreau P
    Haematologica; 2014 Mar; 99(3):e33-4. PubMed ID: 24532044
    [No Abstract]   [Full Text] [Related]  

  • 2. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.
    Moreau P; Avet-Loiseau H; Facon T; Attal M; Tiab M; Hulin C; Doyen C; Garderet L; Randriamalala E; Araujo C; Lepeu G; Marit G; Caillot D; Escoffre M; Lioure B; Benboubker L; Pégourié B; Kolb B; Stoppa AM; Fuzibet JG; Decaux O; Dib M; Berthou C; Chaleteix C; Sebban C; Traullé C; Fontan J; Wetterwald M; Lenain P; Mathiot C; Harousseau JL
    Blood; 2011 Nov; 118(22):5752-8; quiz 5982. PubMed ID: 21849487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.
    Rosiñol L; Oriol A; Teruel AI; Hernández D; López-Jiménez J; de la Rubia J; Granell M; Besalduch J; Palomera L; González Y; Etxebeste MA; Díaz-Mediavilla J; Hernández MT; de Arriba F; Gutiérrez NC; Martín-Ramos ML; Cibeira MT; Mateos MV; Martínez J; Alegre A; Lahuerta JJ; San Miguel J; Bladé J;
    Blood; 2012 Aug; 120(8):1589-96. PubMed ID: 22791289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.
    Cavo M; Tacchetti P; Patriarca F; Petrucci MT; Pantani L; Galli M; Di Raimondo F; Crippa C; Zamagni E; Palumbo A; Offidani M; Corradini P; Narni F; Spadano A; Pescosta N; Deliliers GL; Ledda A; Cellini C; Caravita T; Tosi P; Baccarani M;
    Lancet; 2010 Dec; 376(9758):2075-85. PubMed ID: 21146205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
    Cavo M; Pantani L; Petrucci MT; Patriarca F; Zamagni E; Donnarumma D; Crippa C; Boccadoro M; Perrone G; Falcone A; Nozzoli C; Zambello R; Masini L; Furlan A; Brioli A; Derudas D; Ballanti S; Dessanti ML; De Stefano V; Carella AM; Marcatti M; Nozza A; Ferrara F; Callea V; Califano C; Pezzi A; Baraldi A; Grasso M; Musto P; Palumbo A;
    Blood; 2012 Jul; 120(1):9-19. PubMed ID: 22498745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.
    Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ
    Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Garderet L; Iacobelli S; Moreau P; Dib M; Lafon I; Niederwieser D; Masszi T; Fontan J; Michallet M; Gratwohl A; Milone G; Doyen C; Pegourie B; Hajek R; Casassus P; Kolb B; Chaleteix C; Hertenstein B; Onida F; Ludwig H; Ketterer N; Koenecke C; van Os M; Mohty M; Cakana A; Gorin NC; de Witte T; Harousseau JL; Morris C; Gahrton G
    J Clin Oncol; 2012 Jul; 30(20):2475-82. PubMed ID: 22585692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
    Lee JH; Lee JH; Kim DY; Kim SD; Choi Y; Kang YA; Seol M; Lee KH
    Eur J Haematol; 2012 Jun; 88(6):478-84. PubMed ID: 22364526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.
    Cavo M; Pantani L; Pezzi A; Petrucci MT; Patriarca F; Di Raimondo F; Marzocchi G; Galli M; Montefusco V; Zamagni E; Gamberi B; Tacchetti P; Brioli A; Palumbo A; Sonneveld P
    Leukemia; 2015 Dec; 29(12):2429-31. PubMed ID: 26442610
    [No Abstract]   [Full Text] [Related]  

  • 10. Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.
    Wang M; Giralt S; Delasalle K; Handy B; Alexanian R
    Hematology; 2007 Jun; 12(3):235-9. PubMed ID: 17558699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.
    Terpos E; Christoulas D; Kastritis E; Roussou M; Migkou M; Eleutherakis-Papaiakovou E; Gavriatopoulou M; Gkotzamanidou M; Kanellias N; Manios E; Papadimitriou C; Dimopoulos MA
    Leukemia; 2014 Apr; 28(4):928-34. PubMed ID: 24045498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
    Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
    Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma.
    Dytfeld D; Matuszak M; Lewandowski K; Komarnicki M
    Ann Hematol; 2008 Mar; 87(3):253-4. PubMed ID: 17955241
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD.
    Chim CS; Lie AK; Chan EY; Liu HS; Lau CW; Yip SF; Sim J; Wan TS; Ma ES; Liang R; Tse E; Kwong YL;
    J Hematol Oncol; 2012 Jun; 5():28. PubMed ID: 22682027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new standard of care in newly diagnosed multiple myeloma.
    Richardson PG
    Lancet; 2010 Dec; 376(9758):2043-4. PubMed ID: 21146204
    [No Abstract]   [Full Text] [Related]  

  • 16. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.
    Tacchetti P; Pantani L; Patriarca F; Petrucci MT; Zamagni E; Dozza L; Galli M; Di Raimondo F; Crippa C; Boccadoro M; Barbato S; Tosi P; Narni F; Montefusco V; Testoni N; Spadano A; Terragna C; Pescosta N; Marzocchi G; Cellini C; Galieni P; Ronconi S; Gobbi M; Catalano L; Lazzaro A; De Sabbata G; Cangialosi C; Ciambelli F; Musto P; Elice F; Cavo M;
    Lancet Haematol; 2020 Dec; 7(12):e861-e873. PubMed ID: 33242443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
    Wang YF; Deng SH; Wu T; Xu Y; Zou DH; Wang Y; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jun; 29(6):397-400. PubMed ID: 19031743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients.
    Takashima S; Miyamoto T; Kadowaki M; Ito Y; Aoki T; Takase K; Shima T; Yoshimoto G; Kato K; Muta T; Shiratsuchi M; Takenaka K; Iwasaki H; Teshima T; Kamimura T; Akashi K
    Int J Hematol; 2014 Aug; 100(2):159-64. PubMed ID: 24928523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].
    Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H
    Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.